Circle Pharma Congratulates Dr. William G. Kaelin, Jr., MD on Award of Nobel Prize
Circle Pharma congratulates 2019 Nobel laureate Dr. Bill Kaelin. Dr. Kaelin advises Circle on its work to develop cyclin inhibitors for cancer., [...]
Peptide Therapeutics Near the Sweetest Spots
Peptide therapeutics would seem to occupy a sweet spot between small molecules and biologics. Small molecules, which represent the majority of clinical drugs, preferentially bind hydrophobic pockets or cavities, [...]
Circle Pharma’s work with Pfizer yields new macrocyclic peptides
Circle Pharma Inc. said its first collaboration with Pfizer Inc. has led to the identification of a series of bioavailable macrocyclic peptides capable of acting as potent and cell-permeable modulators of CXCR7. [...]
Circle Pharma Announces Publication in Journal of Medicinal Chemistry of Results from Collaboration with Pfizer Inc.
Results from its collaborative work with Pfizer to develop a potent and orally bioavailable macrocycle modulator have been published [...]
Circle Pharma Announces Appointment of David Spellmeyer, PhD, as Chief Scientific Officer
David Spellmeyer, PhD, has been appointed as Circle Pharma's chief scientific officer [...]
Practical Medicinal Chemistry with Macrocycles – Design, Synthesis, and Case Studies
Cyclic peptide natural products and their synthetic mimics have gained prominence as potential sources of next‐generation therapeutics and biological probes. The size and structural complexity of these compounds sets them apart from common synthetic drugs.
Read online book
Discovery of potent and orally bioavailable macrocyclic peptide-peptoid hybrid CXCR7 modulators.
The chemokine receptor CXCR7 is an attractive target for a variety of diseases. While several small molecule modulators of CXCR7 have been reported, peptidic macrocycles may provide advantages in terms of potency, selectivity, and reduced off-target activity.
Read online article
Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets
As interest in protein–protein interactions and other previously-undruggable targets increases, medicinal chemists are returning to natural products for design inspiration toward molecules that transcend the paradigm of small molecule drugs.
Read online article
Circle Pharma announces expansion of Series A financing and appointment of James C. Lu to its board
An expansion of Series A financing has been completed, with new investors W.I. Harper Group, [...]
Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules
Macrocyclic peptides are considered large enough to inhibit “undruggable” targets, but the design of passively cell-permeable molecules in this space remains a challenge due to the poorly understood role of molecular size on passive membrane permeability.
Read online article